Clinical Report: The Chemsex Knowledge Gap at the Counter
Overview
A survey of community pharmacy professionals in France revealed significant gaps in chemsex-related knowledge and training. While 80% had heard of chemsex, only 67% could define it, and most reported inadequate resources for managing chemsex-related issues.
Background
Chemsex, the use of psychoactive substances to enhance sexual experiences, poses unique challenges in public health, particularly among vulnerable populations. Understanding pharmacists' knowledge and attitudes towards chemsex is crucial for improving prevention and harm reduction strategies. This study highlights the need for enhanced education and resources in pharmacy settings to address these gaps.
Data Highlights
| Finding | Percentage |
|---|---|
| Heard of chemsex | 80% |
| Could define chemsex | 67% |
| Received formal education on chemsex | 11% |
| Recognized intranasal drug use | 90% |
| Identified 'slamming' (IV use) | 18% |
| Felt capable of referring at-risk patients | 66% |
Key Findings
Incorporate the percentage of respondents apprehensive about discussing chemsex.Clinical Implications
Pharmacists should be equipped with better training and resources to address chemsex-related inquiries and provide appropriate counseling. Developing nonjudgmental communication strategies and referral pathways can enhance support for at-risk patients. Addressing stigma and improving knowledge can facilitate better health outcomes in this population.
Conclusion
The study underscores the critical need for enhanced education and resources for pharmacy professionals regarding chemsex. Bridging the knowledge gap can improve prevention efforts and patient care in community pharmacy settings.
Related Resources & Content
- Conexiant, Side Effects: Nobody Trained for This, 2025 -- Chemsex Knowledge Gap
- Archives of Toxicology, In Silico Toxicity Assessment of Phencyclidine (PCP) Derivatives, 2025 -- PCP-type Substances
- Archives of Toxicology, Advancing the Evaluation of Persistence, Bioaccumulation, and Toxicity, 2023 -- Chemical Risk Assessment
- EACS, Chemsex -- Guidelines for Screening and Intervention
- ECDC, Public health considerations on the use of doxycycline for post-exposure prophylaxis, 2026 -- Doxycycline Guidelines
- the analytical scientist — Confronting the Messy Reality of PFAS Regulation
- Implementation and formative evaluation of a peer-led chemsex intervention, Harm Reduction Journal
- EACS: Chemsex
- Public health considerations on the use of doxycycline for post-exposure prophylaxis for bacterial sexually transmitted infections in the EU/EEA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
